Edwards reports one-year PASCAL trial benefit in tricuspid repair
On November 2, 2026, Edwards Lifesciences reported that its PASCAL system outperformed medical therapy in the CLASP II TR study, with findings presented at TCT. At one year, 80% of PASCAL-treated patients had moderate-or-less tricuspid regurgitation, compared with 30% of the control group. The study also recorded an 18-point improvement in Kansas City Cardiomyopathy Questionnaire quality-of-life scores, and Edwards said the six-month primary endpoint had been met.
Why it matters
The report adds comparative one-year clinical evidence for Edwards' tricuspid repair system. PASCAL already had FDA approval for tricuspid repair from October 2026, so the findings provide additional product evidence for investors assessing its commercial prospects.
Key facts
- 1At the one-year assessment, 80% of patients receiving PASCAL had moderate-or-less tricuspid regurgitation, versus 30% among patients given medical therapy alone. investing.com
- 2Edwards said the study achieved its primary six-month endpoint. stocktitan.net
- 3Quality-of-life scores measured with the Kansas City Cardiomyopathy Questionnaire improved by 18 points in the PASCAL group. investing.com
- 4The FDA approved PASCAL for tricuspid valve repair in October 2026. stocktitan.net
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.